REGENXBIO Inc. (RGNX) compared with its closest peers (FDMT, TECX, EIKN, PRME, ZURA). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $873.49M | -3.1 |
| Tectonic Therapeutic, Inc. (TECX) | $709.95M | -5.1 |
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $615.86M | — |
| Prime Medicine, Inc. (PRME) | $610.49M | -2.6 |
| Zura Bio Limited (ZURA) | $554.79M | -4.9 |
| Artiva Biotherapeutics, Inc. (ARTV) | $534.37M | -1.2 |
| Cabaletta Bio, Inc. (CABA) | $530.68M | -1.0 |
| Kyverna Therapeutics, Inc. (KYTX) | $519.48M | -2.6 |
| C4 Therapeutics, Inc. (CCCC) | $492.10M | -1.5 |
| Ocugen, Inc. (OCGN) | $474.75M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
RGNX overview · RGNX earnings · RGNX financials · RGNX KPIs · RGNX investor relations · RGNX ownership · RGNX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.